perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.01.14.24301288;](https://doi.org/10.1101/2024.01.14.24301288) this version posted January 16, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-NC 4.0 International license.

Abstract

 Background: There is a need to establish the role of lipid-lowering agents as a therapeutic option for Parkinson's Disease (PD), but its associations remain elusive. This study investigated genetic variants proxying lipid-lowering agents through HMGCR, NPC1L1, and PCSK9 inhibitors to determine casual associations with PD risk.

 Methods: We utilized a two-sample Mendelian randomization (MR) framework, where low-density lipoprotein (LDL) was the outcome of interest. Genetic associations with LDL were extracted from the Global Lipids Genetics Consortium. Summary statistics for PD were extracted from two GWAS datasets, consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and 1,259 controls in the second dataset. Instrumental variables (IV) were optimized with positive control analyses on cardiovascular and metabolic outcomes. IV-exposure associations from LDL GWAS data were integrated with IV-outcome associations from the PD GWAS data. The inverse variance weighted method was applied. Bayesian colocalization analysis identified target gene regions for LDL and PD. **Results:** Genetic variations in *HMGCR* were significantly associated with a reduced risk of PD (odds ratio [OR] = 0.54, 95% CI 0.34-0.86). However, variation in *HMGCR* was associated with an increased risk of the tremor-dominant (TD) subtype compared to the postural instability/gait difficulty (PIGD) subtype (OR = 8.43, 95% CI 2.12-33.52). There were trends with increased risk for the TD subtype in *NPC1L1* and a decreased risk in *PCSK9* but these findings did not meet the Bonferroni threshold. We identified two single nucleotide polymorphisms (SNPs) in *HMGCR* within the same genomic region of close proximity, with rs12916 as the leading SNP associated with LDL and rs10942735 as the leading SNP associated with PD.

Conclusion: A casual association between *HMGCR* inhibition and reduced overall PD risk was

62 identified, but there were increased the risks of tremor-dominant subtypes.

63

- 64 **Keywords:** Low-density lipoprotein, Parkinson's disease, lipid-lowering drug, mendelian
- 65 randomization, single nucleotide polymorphisms

66 **Introduction**

67 Parkinson disease (PD) is the second most common neurodegenerative disease with progressive 68 nature¹. In 2017, there were 1.02 million incident cases of PD as reported by the Global Burden of Disease2 69 . The determinants of PD are multifactorial, with age-related susceptibilities being the biggest 70 risk factor for PD with a median onset of 60 years of age³. Various studies have identified that genetic 71 susceptibility could modify the effects of environmental stressors. In a recent meta-analysis of 72 genome-wide association studies, 70 variants involved with the folding of alpha-synuclein may 73 contribute to PD risk suggesting a genetic etiology⁴⁻⁶. Unfortunately, there are a lack of therapies that 74 could delay the progression of disease.

75 With recent advancements in surrounding lipid-lowering therapies, targets of cholesterol metabolism 76 may be of interest in PD. Lipids are becoming increasingly recognized to play a significant role in PD. 77 Alpha synuclein is highly expressed in the brain, the second most lipid-rich organ, and exhibits binding 78 properties with lipid membranes, thereby altering their structure and resulting in the formation of 79 toxic alpha-synuclein oligomers^{7,8}. There is much interest on how lipid aberrations could contribute 80 to PD, as several risk genes exert known lipid-related functions⁹. An increase in serum lipids such as 81 low-density lipoprotein (LDL) and its metabolites are correlated with oxidative stress in the brain 82 through the generation of Lewy bodies, though there are conflicting studies suggesting that 83 cholesterol and triglyceride levels are neuroprotective¹⁰⁻¹³. The role of lipid-lowering agents, such as 84 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1) 85 inhibitor, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may be of therapeutic 86 interest to ameliorate PD risk by targeting brain cholesterol metabolism and associated pathways but

87 further studies are required to clarify these outcomes due to the bidirectional effect of lipids in PD¹⁴.

88 In this study, we leveraged genetic variants proxying LDL lowering agents through HMGCR, NPC1L1, 89 and PCSK9 inhibitors to determine its association with PD. Genetic proxies have been successfully 90 used to study the effect of lipid-lowering drugs which target alleles encoding various molecular stages 91 in VLDL trafficking and cholesterol metabolism¹⁵. To establish casual associations of modifiable 92 exposures such as genetic proxies for lipid-lowering therapies in PD, we utilized a two-sample 93 Mendelian randomization (MR) framework to reduce reverse causation biases and less likely to be 94 influenced by confounding factors¹⁵. This study aimed to investigate the relationship between lipid-95 lowering medication and PD.

96

97 **Methods**

98 **Study Design**

 MR is a statistical technique that utilizes genetic variants as instrumental variables (IVs) to establish causal inferences between exposures and outcomes. This study employed the two sample MR framework to investigate the effects of genetic variation in lipid-lowering drug targets on the risk of 102 Parkinson's disease (PD)¹⁶. Exposure and outcome data were extracted from public genome wide association study (GWAS) summary datasets conducted on two independent, non-overlapping populations. risk of Parkinson's disease. The details of the framework are presented in **eFigure 1**.

105 **LDL GWAS Data**

 Due to the unavailability of GWAS data on the exposure (protein targets of lipid-lowering drugs) and considering reducing LDL levels is a confirmed physiological response to lipid-lowering drug treatment, our study opts to use the available LDL as a biomarker of interest. This choice enables us to infer the effects of genetic variations in lipid-lowering drugs on the. Genetic associations with LDL were extracted from the largest GWAS dataset conducted by the Global Lipids Genetics Consortium, involving 1.3 million individuals of European ancestry. The details of primary study is provided in 112 reference¹⁷.

Parkinson's Disease GWAS Data

 The summary statistics for PD were extracted from the two GWAS datasets, which were published by the International Parkinson's Disease Genomics Consortium. The first GWAS dataset consisted of 116 1,843 cases and 216,630 controls⁶. The other GWAS dataset focused on the motor subtype of PD consisted of 1,570 cases and 1,259 controls, where the tremor-dominant (TD) was defined as 1 and considered the case group, and the postural instability/gait difficulty (PIGD) was defined as 0 and 119 served as the control group¹⁸. Both GWAS dataset were conducted on individuals of European ancestry to minimize potential bias from population stratification.

Instrument Selection

 The IVs in this study were screened for the genes that encode lipid-lowering drug target proteins. Variations within and around these genes were used to assess the effect of drug use on exposure factors and outcomes. Three major classes of lipid-lowering drugs were identified, including 3- hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1)

- inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Detailed information
- about the protein targets and encoding genes for these drugs is provided in **Table 1**.

128 The single-nucleotide variations (SNVs) were designated within each encoding gene (within ±100kb base pairs of the gene location). Following this, variants with p-values greater than 5*10-8 and a minor allele frequency (MAF) below 0.01 werwe excluded in the GWAS data for LDL. The remained 131 variants for each lipid-lowing drug target were selected as IVs and clumped with an R^2 of 0.1, a window size of 10000 kb, and the reference population set to EUR. The detailed screening process of IVs for lipid-lowering drug is shown in **Figure 1**.

Positive Control Analyses

135 In order to substantiate IVs selection, positive control analyses were performed using hyperlipidemia and coronary artery disease (CAD) as outcomes. Furthermore, three obesity-related traits were used as additional outcomes for validation, including body mass index (BMI), waist circumference (WC), and hip circumference (HC).

Statistical Analysis

 The present investigation integrated the IV-exposure association derived from the LDL GWAS data with the IV-outcome association obtained from the Parkinson's disease GWAS data to create 142 harmonized data for the MR study. To safeguard the validity of the IV, it is crucial to adhere to three fundamental assumptions. The initial assumption, known as relevance, necessitates that the genetic variants are significantly associated with the exposure. Evaluation of the strength of the IV was conducted through the computation of F statistics, derived as the square of the beta divided by the

 square of the standard error, with F statistics exceeding 10 indicatives of robust IV strength. The 147 second assumption, independence, posits that the genetic variants remain unaffected by potential confounding factors, a condition typically fulfilled owing to the random assortment of genetic variants during conception. The third assumption, exclusion restriction, asserts that the variants exclusively influence the outcome through the designated exposure, thereby precluding horizontal pleiotropy. Evaluation of horizontal pleiotropy was conducted utilizing the MR Egger method, and non-significant results suggest the absence of horizontal pleiotropy. In instances where all three assumptions are met, the Inverse Variance Weighted (IVW) method is applied to yield unbiased causal estimates pertaining to the associations between exposures and outcomes.

 The F-statistic was calculated by dividing the square of beta by the square of the standard error, where an F-statistic value greater than 10 indicating sufficient instrument strength. The Cochran Q test was employed to assess heterogeneity within IVs, and non-significant results signify the absence of heterogeneity. To mimic the LDL-lowering effects of lipid-lowering drugs, the MR estimates were standardized to a 1 mmol/L decrease in LDL. Following Bonferroni corrected principle, the significance level of multiple testing for 3 drugs classes was set as *p* value < 0.017 (0.05/3).

 For the lipid-lowering drugs identified to be associated with Parkinson's disease, Bayesian colocalization analysis was conducted specifically within the target gene region for LDL and Parkinson's disease. Another sensitivity analysis was the leave-one-out method, which entails systematically excluding each variant within the drug's target gene region and subsequently calculating the meta-effects of the remaining variants. The absence of statistically significant changes in MR estimates following the removal of each variant implies the robustness of the obtained results.

All analyses were performed in R (version = 4.3.1), mainly utilizing the TwoSampleMR (version = 0.5.7)

and coloc (version = 5.2.3) packages. This study follows the Strengthening the Reporting of

Observational Studies in Epidemiology (STROBE) MR guidelines.

Data Availability

- All GWAS data analyzed in this study are publicly available. The LDL GWAS data is downloaded from the website of the Global Lipids Genetics Consortium (https://csg.sph.umich.edu/willer/public/glgc- lipids2021). The PD GWAS data is released in the resources page of International Parkinson's Disease Genomics Consortium [\(https://www.pdgenetics.org/resources\)](https://www.pdgenetics.org/resources). The GWAS data for positive control analyses are available through the IEU Open-GWAS Project database [\(https://gwas.mrcieu.ac.uk/\)](https://gwas.mrcieu.ac.uk/). The corresponding GWAS-ids are ebi-a-GCST90104006 for hyperlipidemia; ebi-a-GCST003116 for coronary artery disease; ieu-b-40 for BMI; ukb-b-9405 for WC and ukb-b-15590 for HC. All code for MR analyses is available in a GitHub repository.
-

Results

Instrument Selection

 For the primary analysis, 22 variants were selected to proxy LDL lowering through inhibition of HMGCR (mean F-statistic of 194), 12 for NPC1L1 (mean F-statistic of 109), and 37 for PCSK9 (mean F-statistic of 286). Detailed data of the IVs to proxy lipid-lowering drugs are shown in **eTable 1**.

```
185 Positive Control Analyses
```
 As shown in **Figure 2**, genetic variations in *HMGCR*, *NPC1L1*, and *PCSK9* were significantly associated with a reduced risk of hyperlipidemia and CAD (**Figure 2, panels A and B**). For obesity-related traits (**Figure 2, panels C-E**), genetic variation in *HMGCR* was significantly correlated with increased BMI, WC, and HC. However, genetic variations in *NPC1L1* and *PCSK9* demonstrated no apparent correlation with BMI, WC, and HC. Positive control analysis data for each lipid-lowering drug class are available in **eTable 2-6**.

Effects of Genetic Variation in lipid-lowering drug Targets on PD risk

 We conducted MR analysis using two PD GWAS datasets, and the results are illustrated in **Figure 3**. For the unstratified PD dataset, the MR analysis results revealed a significant association between genetic variation in *HMGCR* and a reduced risk of PD at the Bonferroni-corrected threshold (odds ratio [OR] = 0.54, 95% CI 0.34-0.86, *p* = 0.009, **Figure 3A**). However, there was no apparent correlation between genetic variations in *NPC1L1* and *PCSK9* and the risk of PD.

 Interestingly, further MR analysis on the PD dataset stratified by motor function showed that, compared to the PIGD subtype, genetic variation in *HMGCR* was significantly associated with an increased risk of the TD subtype at the Bonferroni-corrected threshold (OR = 8.43, 95% CI 2.12-33.52, *p* = 0.0025, **Figure 3B**). Additionally, genetic variation in *NPC1L1* showed a trend toward increased risk for the TD subtype (OR = 13.09, 95% CI 1.03-166.64, *p* = 0.0475), while genetic variation in *PCSK9* exhibited a trend toward decreased risk for the TD subtype (OR = 0.28, 95% CI 0.08-0.94, *p* = 0.0398). Unfortunately, the *p*-values for MR analysis of these two gene variations exceeded the Bonferroni-205 corrected threshold $(p < 0.017)$.

 As evidence suggested that cognitive function declines more rapidly, and prognosis is worse in PIGD 207 patients compared to TD patients. Our analysis suggests that the use of HMGCR and NPC1L1 inhibitors may contribute to the transition of PD patients from PIGD subtype to TD subtype, while the use of PCSK9 inhibitors may pose a risk of worsening PD. No heterogeneity or pleiotropy was detected within the IVs in both PD GWAS datasets (**Figure 3**, *p*-values for heterogeneity > 0.05, *p*-values for pleiotropy > 0.05). Detailed MR analysis data are presented in **eTable 7-9**.

Sensitivity Analysis

 Colocalization analysis was conducted for LDL and PD within *HMGCR* (**eTable 10**), as well as co- localization analysis for LDL and PD motor subtype within both *HMGCR* and *PCSK9* (**eTable 11**). The results of the colocalization analysis indicated a low probability of shared random variation between LDL and PD within *HMGCR* (0.87%), and similarly low probabilities within both *HMGCR* and *PCSK9* for the motor subtype of PD (5.31% and 8.22%, respectively).

 The findings suggest that there is no high probability of shared causal variants for LDL and PD (including the PD motor subtype) within the coding regions of *HMGCR* and *PCSK9*. However, in the regional plot illustrating the associations of LDL and PD within ±100kb of *HMGCR*, rs12916 emerged as the leading SNP associated with LDL, while rs10942735 wasidentified as the leading SNP associated with PD within the same genomic region. Notably, these two leading SNPs were in close proximity, that revealed a trend of colocalization between LDL and PD (**eFigure 2**).

 Additionally, in the PD GWAS datasets, leave-one-out sensitivity analyses were conducted for the genetic variations in *HMGCR* and *PCSK9*. The analyses demonstrated the robustness of the results,

226 indicating that after excluding each SNP, the overall error lines show minimal changes (all error lines 227 are either to the right or left of 0), as shown in **eFigure 5-7**.

228

229 **Discussion**

 This study investigated the effects of genetic variations in lipid-lowering drugs on the PD risk using a 231 combination of LDL genetic dataset in ~1,300,000 participants and two PD genetic datasets, consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and 1,259 controls in the second dataset. To the best of our knowledge, this is one of the largest studies with strong validation suggesting a causal association between HMGCR inhibition and a reduced risk of PD. Besides, this study was the first MR to investigate the association between genetic variation in lipid-lowering drug and the subtypes of PD.

237 A handful of literature has explored the association between lipid-lowering drugs or serum lipid levels 238 and PD, yet the results have been inconsistent $19-26$. In a MR study using a Danish dataset, no 239 association was detected between LDL and the risk of PD, whereas a separate MR study conducted 240 by a Swedish team suggested a causal inverse association of LDL with PD risk^{19,27}. Another recent MR 241 study did not project an elevated risk of PD with statin exposure²⁰. However, the results lacked 242 sufficient precision to conclusively support preventive benefits. Nevertheless, this does not negate 243 the potential advantages of on-target effects associated with statin use for PD prevention through 244 alternative mechanisms²⁰. However, all of these MR studies have their own statistical limitations. 245 Other non-MR studies have also reported varied conclusions²¹⁻²⁵. Interpreting the above studies

246 alongside our study results, which showed that only HMGCR inhibition, not NPC1L inhibition and 247 PCSK9 inhibition, was correlated with a reduced risk of PD. The result provided evidence that HMGCR 248 inhibitors may modify the pathogenesis of PD through a mechanism different from lowering LDL. 249 Indeed, multiple studies have proposed the protective effects of HMGCR inhibitors on α -synuclein 250 aggregation through mechanisms such as antioxidation and promotion of neural repair²⁸⁻³⁰. Other 251 suggested mechanisms involve HMGCR inhibitors preventing neuronal injury by mitigating microglia 252 and autophagy activation³¹⁻³³. As HMGCR inhibitors can cause a dose-dependent reduction in 253 coenzyme Q10, the protective effects of HMGCR inhibitors may be compromised by mitochondrial 254 dysfunction if the dose surpasses a specific threshold³⁴. Nonetheless, this potential explanation for 255 the inconsistency in previous studies warrants further investigation.

256 Another discovery from this study implied that incorporating HMGCR inhibitors may facilitate the shift 257 of PD patients from the less favorable PIGD subtype to the more favorable TD subtype. The 258 mechanisms behind the observations in the current study were not fully understood and necessitate 259 additional research. However, previous studies have pointed to the involvement of various neural 260 pathways in contributing to the PIGD phenotype of Parkinson's disease³⁵⁻³⁷. For example, some 261 literature hinted at a connection between the severity of PIGD and amyloid β pathology^{35,38}. The 262 neuroprotective impact of HMGCR inhibitors on amyloid β-induced neurotoxicity may offer a partial 263 explanation for the effect observed on the PIGD subtype³⁹. Other studies suggested that elevated 264 GABA levels or reduced acetylcholine may play a role in the development of the PIGD phenotype in 265 Parkinson's disease, and HMGCR inhibitors might be involved in modifying the pathogenesis^{40,41}. 266 Given functional network alterations within cerebro-cerebellar motor pathways were identified 267 among PD motor subtypes, we contemplate whether HMGCR inhibitors contribute to the alterations,

268 warranting further exploration in future studies³⁷.

 This study possesses several strengths. First, it involves large sample sizes from public GWAS datasets for analysis. The inclusion of such substantial and robust data enables study replication and diminishes random errors. In addition, all the GWAS datasets used were conducted on individuals of European ancestry, thereby minimizing potential biases arising from population stratification. 273 Secondly, the two-sample MR study design may overcome the challenges of confounding between 274 the exposure and outcome when estimating the causal exposure-outcome association. It also offers 275 an opportunity to enhance statistical power and avoid reverse causality. Third, by performing a series of positive control analyses and sensitivity analyses that considered different patterns of pleiotropy, 277 this study enhanced the robustness of the results, thereby reinforcing the evidence supporting our findings.

 The study has several limitations. First, MR study needed to fulfill the instrumental variable assumptions which cannot be empirically verified. Even though rigorous statistical methods were employed, it is important to note that the complete exclusion of pleiotropy and bias effects cannot be guaranteed. Second, the lipid-lowering drug effect predicted by MR cannot be directly juxtaposed with the pharmacological effect observed in real life practice. The exposure instrumented by genetic variants persists throughout lifetime, whereas pharmacological intervention influences only a specific period of life. Consequently, the results of this study should be interpreted as evaluating the long- term modulation effects of drug target proteins. Third, lipid-lowering drugs may modify PD through interactions with other protein targets not captured in this MR study or via different mechanisms. Fourthly, the dataset utilized in this study only comprised individuals of European ancestry, limiting

- 289 the generalizability of the results to other ethnic groups. However causal effects are expected to be
- consistent across settings unless the mediating mechanisms differ, although the extent of response
- may vary.
-
- **Conclusion**
- The two way Mendelian Randomization result identified the casual association between genetic
- variations in *HMGCR* and PD, which suggested that lipid-lowering drugs may play a role in lowering
- risks of PD. However, the risk of TD subtypes are higher compared to PIGD subtypes, suggesting the
- bidirectional effects of the lipid-lowering drugs.

Ethical approval statement

- None.
- **Availability of data and materials**
- Data are publicly available and can be accessed with the GWASID.
- **Conflicts of Interest**
- None
- **Acknowledgements**
- None

Funding

- This research received no specific grant from any funding agency in the public, commercial, or not-
- for-profit sectors.
- **Guarantor Statement**
- All authors approved the final version of the manuscript.

Author contributions

- L S, YF, JD Z: conception of study, preparation of figures, study design, data contribution, statistical
- analysis, data interpretation, manuscript drafting, and critical revision of the manuscript.

- Y L, HL C, H H: literature search, data interpretation, literature search, data collection, manuscript
- drafting.
- BMY C, G T: critical revision of the manuscript.
- OHI C, JD Z: conception of study and literature search, study design, data collection, and critical
- revision of manuscript, study supervision.

References

- 1. Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson's Disease: A Review from Pathophysiology to Treatment. *Mini Rev Med Chem* 2020; **20**(9): 754-67.
- 2. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and
- years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017:
- a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1789- 858.
- 3. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest
- risk factor? *Ageing Res Rev* 2014; **14**(100): 19-30.
- 4. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? *J Neurol Neurosurg Psychiatry* 2013; **84**(4): 409-15.
- 5. Kara E, Kiely AP, Proukakis C, et al. A 6.4 Mb duplication of the alpha-synuclein locus causing
- frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. *JAMA Neurol* 2014;
- **71**(9): 1162-71.
- 6. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and
- heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*
- *Neurol* 2019; **18**(12): 1091-102.
- 7. Fanning S, Selkoe D, Dettmer U. Parkinson's disease: proteinopathy or lipidopathy? *NPJ Parkinsons Dis* 2020; **6**: 3.
- 8. Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of alpha-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. *Mol Cell* 2019; **73**(5): 1001-14 e8.

- 9. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of
- Parkinson disease. *Neurology* 2008; **70**(21): 1972-9.
- 10. Xicoy H, Klemann CJ, De Witte W, Martens MB, Martens GJ, Poelmans G. Shared genetic etiology
- between Parkinson's disease and blood levels of specific lipids. *NPJ Parkinsons Dis* 2021; **7**(1): 23.
- 11. Jin U, Park SJ, Park SM. Cholesterol Metabolism in the Brain and Its Association with Parkinson's
- Disease. *Exp Neurobiol* 2019; **28**(5): 554-67.
- 12. Galper J, Dean NJ, Pickford R, et al. Lipid pathway dysfunction is prevalent in patients with
- Parkinson's disease. *Brain* 2022; **145**(10): 3472-87.
- 13. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease
- risk: A statin-free cohort study. *Mov Disord* 2018; **33**(8): 1298-305.
- 14. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating Lipid-Lowering Drug Targets for
- Parkinson's Disease Prevention with Mendelian Randomization. *Ann Neurol* 2020; **88**(5): 1043-7.
- 15. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nat Rev Methods Primers* 2022; **2**.
- 16. Schmidt AF, Finan C, Gordillo-Maranon M, et al. Genetic drug target validation using Mendelian randomisation. *Nat Commun* 2020; **11**(1): 3255.
- 17. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association
- studies of lipids. *Nature* 2021; **600**(7890): 675-9.
- 18. Alfradique-Dunham I, Al-Ouran R, von Coelln R, et al. Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. *Neurol Genet* 2021; **7**(2): e557.
- 19. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen AJb. Low LDL cholesterol, PCSK9
- and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian

- randomisation study. 2017; **357**.
- 20. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating lipid-lowering drug targets for
- Parkinson's disease prevention with mendelian randomization. 2020; **88**(5): 1043-7.
- 21. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease
- risk: a statin-free cohort study. 2018; **33**(8): 1298-305.
- 22. Lee HJ, Han K, Kim YW, Yang SN, Yoon SYJP, Disorders R. Association between lipid levels and the
- risk of Parkinson's disease in individuals with diabetes mellitus: A nationwide population-based
- cohort study. 2023; **117**: 105881.
- 23. Nguyen TTH, Fournier A, Courtois É, et al. Statin Use and Incidence of Parkinson's Disease in
- Women from the French E3N Cohort Study. 2023.
- 24. Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson's disease: A systematic review and meta-analysis. 2019; **98**(12).
- 25. Jeong SH, Lee HS, Chung SJ, et al. Effects of statins on dopamine loss and prognosis in Parkinson's
- disease. 2021; **144**(10): 3191-200.
- 26. Zhao Y, Gagliano Taliun SAJFiN. Lipid-lowering drug targets and Parkinson's disease: A sex-specific
- Mendelian randomization study. 2022; **13**: 940118.
- 27. Fang F, Zhan Y, Hammar N, et al. Lipids, Apolipoproteins, and the risk of Parkinson disease: a
- prospective cohort study and a Mendelian randomization analysis. 2019; **125**(6): 643-52.
- 28. Eriksson I, Nath S, Bornefall P, Giraldo AMV, Öllinger KJEjocb. Impact of high cholesterol in a
- Parkinson's disease model: Prevention of lysosomal leakage versus stimulation of α-synuclein
- aggregation. 2017; **96**(2): 99-109.
- 29. Yan J, Sun J, Huang L, Fu Q, Du GJJonr. Simvastatin prevents neuroinflammation by inhibiting N-

methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. 2014; **92**(5): 634-40.

30. Tan W, Xue-bin C, Tian Z, et al. Effects of simvastatin on the expression of inducible nitric oxide

synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of

Parkinson disease. 2016; **126**(3): 278-86.

 31. Lu D, Shen L, Mai H, et al. HMG-CoA reductase inhibitors attenuate neuronal damage by suppressing oxygen glucose deprivation-induced activated microglial cells. 2019; **2019**.

32. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar AJB. The effects of

statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. 2020;

46(3): 309-25.

33. Kang SY, Lee S-B, Kim HJ, Kim H-T, Yang HO, Jang WJNL. Autophagic modulation by rosuvastatin

prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. 2017; **642**: 20-6.

 34. Apostolopoulou M, Corsini A, Roden MJEjoci. The role of mitochondria in statin-induced myopathy. 2015; **45**(7): 745-54.

 35. Zuo L-J, Piao Y-S, Li L-X, et al. Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and

neurotransmitters. 2017; **7**(1): 44872.

36. Wen P, Li M, Xiao H, et al. Low-frequency stimulation of the pedunculopontine nucleus affects

gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats.

2015; **600**: 62-8.

 37. Basaia S, Agosta F, Francia A, et al. Cerebro-cerebellar motor networks in clinical subtypes of Parkinson's disease. 2022; **8**(1): 113.

38. Müller ML, Frey KA, Petrou M, et al. β-amyloid and postural instability and gait difficulty in

- Parkinson's disease at risk for dementia. 2013; **28**(3): 296-301.
- 39. Li HH, Lin CL, Huang CN. Neuroprotective effects of statins against amyloid β-induced
- neurotoxicity. *Neural Regen Res* 2018; **13**(2): 198-206.
- 40. Welter M-L, Demain A, Ewenczyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson's
- disease: a double-blind, randomised study. 2015; **262**: 1515-25.
- 41. El-Dessouki AM, Galal MA, Awad AS, Zaki HFJMn. Neuroprotective effects of simvastatin and
- cilostazol in L-methionine-induced vascular dementia in rats. 2017; **54**: 5074-84.

Figure 1 Instrument Selection for Lipid-lowering Drug Classes

The black line represents the DNA strand. The raised black box indicates the tar get gene, and the box with dashed line encompasses the region of ±100kb base pairs around the target gene. Each inverted triangle represents a genetic varian t. Disappearing of inverted triangles indicates the exclusion of variants. HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; MAF, minor allele frequency; NPC1L1, N iemann-Pick C1-like 1; PCSK9, proprotein convertase subtilisin/kexin type.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.01.14.24301288;](https://doi.org/10.1101/2024.01.14.24301288) this version posted January 16, 2024. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

Figure 2 Estimated Effects of Genetic Variation in Lipid-lowing Drug Targets on Lipid Metabolism-Related Traits (Panel A-B) and Obesity-Related Traits (Panel C-E)

A. Genetic variation in lipid-lowing drug targets on hyperlipidemia

B. Genetic variation in lipid-lowing drug targets on CAD

C. Genetic variation in lipid-lowing drug targets on BMI

D. Genetic variation in lipid-lowing drug targets on WC

E. Genetic variation in lipid-lowing drug targets on HC

Proxy gene is the gene that encodes the drug target protein. The estimated bet a coefficients on BMI, WC, and HC are expected to be in agreement with the e vidence from clinical trials, that is, taking in HMGB1 inhibitor (ie, lovastatin) cont ributes to weight gain, and taking NPC1L1 inhibitor (ie, ezetimibe) and PCSK9 in hibitor (ie, alirocumab) has no effect on weight. BMI, body mass index; CAD, co

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.01.14.24301288;](https://doi.org/10.1101/2024.01.14.24301288) this version posted January 16, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-NC 4.0 International license.

ronary artery disease; HC, hip circumference; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; IVs, instrumental variables; NPC1L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type; SNVs, single-nucleot ide variations; WC, waist circumference.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.01.14.24301288;](https://doi.org/10.1101/2024.01.14.24301288) this version posted January 16, 2024. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

Figure 3 Estimated Effects of Genetic Variation in Lipid-lowing Drug Targets on Parkinson's disease

A. Genetic variation in lipid-lowing drug targets on all types of PKD

B. Genetic variation in lipid-lowing drug targets on TD vs PIGD

Proxy gene is the gene that encodes the drug target proteins. *P* < 0.01 indicate s statistical significance, and 0.01 < *p* < 0.05 indicates suggestive significance. *P* for heterogeneity <0.05 indicates possible heterogeneity, whereas *p* for intercept <0.05 indicates substantial bias from pleiotropy. HMGCR, 3-hydroxy-3-methylglutar yl-CoA reductase; IVs, instrumental variables; MR, mendelian randomization; NPC1 L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisi n/kexin type; PIGD, postural instability/gait difficulty; PKD, Parkinson's disease; SN Vs, single-nucleotide variations; TD, tremor-dominant.

Table 1 Detailed Information of Lipid-lowering Drug Classes, Targets, and Encodi ng Genes.